DexCom Q1 Results and Raised Guidance Bolster Bull Case, but Risks Persist

What happened

DexCom reported Q1/26 revenue growth of 15% and operating income growth of 91%, raising full-year 2026 guidance for both revenue and margins. The stock has fallen 15% from prior levels, making it more attractive at current valuations, according to a recent Seeking Alpha analysis. The DeepValue report rates DexCom a "Potential Buy" with a base case of $80, citing improved fundamentals, international expansion, and new Type 2 coverage as growth drivers. However, risks remain including an unresolved FDA warning letter, potential CMS competitive bidding pressure on pricing, and the need to execute on margin expansion to 63-64% gross margins. The combination of strong quarterly results and a lower share price creates a more favorable risk/reward, but execution on regulatory and operational fronts is critical.

Implication

For investors, the Q1 results and raised guidance validate the thesis that DexCom can grow 11-13% in 2026 while expanding margins. The 15% price decline from prior levels offers a modest margin of safety, but the unresolved FDA warning letter and impending CMS competitive bidding keep the risk elevated. Near-term catalysts include the February 12, 2026 earnings call with detailed 2026 guidance and FDA communication on the warning letter. The stock trades at ~38x EPS, pricing in durable growth but not a collapse. A disciplined position sizing is warranted, with a re-assessment window of 6-12 months. The bull case of $95 assumes rapid Stelo adoption and type 2 expansion, while the bear case of $55 assumes margin stagnation and regulatory escalation.

Thesis delta

The Q1 results and guidance raise the probability of achieving the base case, but they do not eliminate the key risks. The thesis remains that DexCom can deliver 11-13% growth and 63-64% gross margins, but the stock still embeds a regulatory and GLP-1 discount. The improved near-term performance increases confidence, but the outcome hinges on FDA resolution and CMS impact.